Stage 4 lung adenocarcinoma: complete response on immunotherapy combination

Patient Info: Anonymized, Male | Stage IV

Biomarkers: No targetable mutation found. Tissue showed TP53/ARID1A; liquid biopsy added KEAP1, and SMARCA4. PD-L1 not evaluable.

Metastatic Site: bilateral lung nodules, left adrenal gland

As of May 2024, metastatic lung adenocarcinoma had a complete radiologic response lasting more than 14 months on pembrolizumab maintenance, and a new PET-avid lung nodule was benign inflammation rather than cancer.

PubMed CentralRead more →

Small cell lung cancer with SIADH that progressed after an initial response to treatment

Patient Info: Anonymized, female, 60s | Stage IV

Metastatic Site: liver

The cancer progressed with disseminated liver metastases, and she died from liver failure in February 2021.

PubMed CentralRead more →

Stage IV lung adenocarcinoma with brain metastases and an aortic blood clot

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: KRAS ; EIF1AZ mutation; PD-L1 30%

Metastatic Site: brain

She remained in active care after whole-brain radiation, with systemic chemo-immunotherapy planned for Stage IV lung adenocarcinoma.

PubMed CentralRead more →

Stage 4 lung cancer stable on durvalumab immunotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Metastatic Site: brain, pancreas, liver

Stage IV small cell lung cancer remained stable after durvalumab, platinum chemotherapy, radiation, and 1 year of durvalumab monotherapy; severe right sternoclavicular joint arthritis resolved after infliximab, and immunotherapy was suspended for 1 year.

PubMed CentralRead more →

Stage 4 lung adenocarcinoma: brain surgery followed by immunotherapy response

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1-positive; EGFR wild-type/no mutation; ALK rearrangement not detected; TTF-1-positive; Napsin A-positive

Metastatic Site: brain

As of March 2024, after 31 cycles of zimberelimab, the lung lesion had shown partial response, brain metastasis had not recurred, and the patient had 24-month progression-free and intracranial recurrence-free survival with normal quality of life.

PubMed CentralRead more →

Lung cancer treated with targeted therapy: rare blood vessel inflammation as a side effect

Patient Info: Anonymized, Female | Stage IV

Biomarkers: BRAF mutation

Metastatic Site: pleura

She initially achieved a complete response. After vasculitis treatment, targeted therapy continued and a partial lung-cancer response remained maintained without vasculitis recurrence.

PubMed CentralRead more →

Stage IV ALK Lung Adenocarcinoma: Niko's Patient Story

Patient Info: Niko, Female | Stage IV

Biomarkers: ALK mutation/rearrangement

Metastatic Site: Lymph nodes; Brain

As of May 2024, Niko’s Stage IV ALK-positive lung adenocarcinoma was controlled on ALK-targeted therapy, with no brain lesion seen on follow-up MRI/PET-CT and active disease described as dormant/stable.

YouTube (ZH search)Read more →

Stage IV small cell lung cancer with metastases involving bone and both eye muscles

Patient Info: Anonymized, male, 40s | Stage IV

Metastatic Site: bone; bilateral extraocular muscles (orbits)

He died 5 months after presenting with bilateral orbital involvement while receiving palliative treatment for Stage IV small cell lung cancer.

PubMed CentralRead more →

Stage IV lung adenocarcinoma complicated by visceral leishmaniasis during chemotherapy

Patient Info: Anonymized, male, 50s | Stage IV

Biomarkers: EGFR wild-type; ALK negative; ROS negative; PD-L1 negative

Imaging showed progression while maintenance pemetrexed was temporarily interrupted; pemetrexed was then restarted during treatment for visceral leishmaniasis.

PubMed CentralRead more →

ALK-positive lung adenocarcinoma complicated by crizotinib-associated kidney and liver cysts

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: ALK fusion

Metastatic Site: bone

After switching from crizotinib to alectinib, the lung cancer and hilar lymph nodes remained stable at the latest follow-up described.

PubMed CentralRead more →

Jeff

Patient Info: Jeff, Male | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain|bones|lymph nodes

The lung mass shrank, 5 brain lesions and the involved lymph node had no evidence of disease, and Jeff described his condition as stable while continuing osimertinib and bone-strengthening infusions.

Lung Cancer Research FoundationRead more →

Rare non-small cell lung cancer with TTF-1 and p40 coexpression and later bone recurrence

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: PD-L1 TPS 60%; ALK negative; ROS1 negative

Metastatic Site: lumbar vertebrae

The cancer recurred in the lumbar vertebrae about 4 months after surgery, and he died from cancer 9 months after the operation.

PubMed CentralRead more →

BRAF V600E lung adenocarcinoma with a response lasting more than 5 years on dabrafenib and trametinib

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: BRAF ; PD-L1 TPS 100%

Metastatic Site: pleura

More than 5 years after her initial presentation, dabrafenib plus trametinib remained effective with no trend toward tumor progression.

PubMed CentralRead more →

SMARCA4-deficient undifferentiated lung cancer with pleural disease and later spinal metastasis

Patient Info: Anonymized, male, 40s | Stage IV

Biomarkers: BRCA1 p.S1796 variant; TP53 p.; tumor mutational burden 12.6

Metastatic Site: spine

After chemotherapy and one cycle of nivolumab, a new 4.5 cm spinal metastasis caused cord compression and required surgery; further outpatient treatment was planned.

PubMed CentralRead more →

Stage IV BRAF-mutated lung adenocarcinoma responding to second-line chemo-immunotherapy

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: BRAF exon 15 p.T599dup; PD-L1 5%

Metastatic Site: pleura, pericardium

After progression on BRAF/MEK-targeted therapy, second-line chemo-immunotherapy produced a partial response that was still ongoing after about 1 year of second-line treatment.

PubMed CentralRead more →

ALK-positive lung cancer treated with alectinib throughout pregnancy

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ALK rearrangement / fusion-positive

Metastatic Site: pleura; liver; bone; brain

Alectinib produced a complete radiologic response and maintained intracranial control through pregnancy. She delivered a healthy infant at 37 weeks, with normal development at 26 months.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Anne's Patient Story

Patient Info: Anne Laporte, Female | Stage IV

Biomarkers: EGFR-mutated; several additional mutations mentioned but not specified

Metastatic Site: Spine; liver; lymph nodes

As of March 2024, Anne was living with Stage IVB EGFR-mutated NSCLC on a clinical trial after progression on Tagrisso, with early signs of decreased tumor burden and major improvement in pain.

The Patient StoryRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Ashley's Patient Story

Patient Info: Ashley, Female | Stage IV

Biomarkers: EGFR T790M mutation

Metastatic Site: Both lungs / bilateral lung nodules

As of March 2024, Ashley was living with Stage IV EGFR-mutated NSCLC controlled on daily Tagrisso for 43 months, with stable scans but no cancer-free or NED claim.

The Patient StoryRead more →

EGFR L858R/S768I lung adenocarcinoma with more than 5 years of survival after targeted therapy

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR L858R and S768I compound mutation

Metastatic Site: bone, brain

He died on August 15, 2022, about 5 years and 4 months after his April 2017 presentation; afatinib had provided more than 3 years of disease control before later bone and brain progression.

PubMed CentralRead more →

Stage IV ALK Lung Adenocarcinoma: Keegan's Survivor Story

Patient Info: Keegan Murphy, Male, 40s | Stage IV

Biomarkers: ALK fusion mutation

Metastatic Site: Lungs; lymph nodes; ribs/bone; abdomen

As of March 2024, Keegan had gone from Stage IV ALK-positive lung adenocarcinoma with tumors in the lungs, lymph nodes, ribs, and abdomen to no evidence of disease after alectinib and surgery.

MD AndersonRead more →

Metastatic lung cancer responding to pembrolizumab despite multiple immune-related side effects

Patient Info: Anonymized, male, 60s | Stage IV

Metastatic Site: right adrenal gland

Later PET/CT showed no FDG uptake in the primary lung lesion or the right adrenal metastasis after pembrolizumab had been stopped for toxicity.

PubMed CentralRead more →

Stage IV lung adenocarcinoma presenting as a painful thigh metastasis

Patient Info: Anonymized, female, 40s | Stage IV

Metastatic Site: right thigh soft tissue/muscle, bilateral iliac bones…

After 9 months of therapy, the lung lesion had a partial response and the painful thigh mass had markedly decreased, although she remained unable to walk.

PubMed CentralRead more →

Stage IV Non-Small Cell Lung Cancer: Tim's Patient Story

Patient Info: Tim Monds, Male, 50s | Stage IV

Biomarkers: High PD-L1 expression

Metastatic Site: Other lung lobes / lung nodules

As of March 2024, Tim Monds was identified as a Stage IV lung cancer survivor involved in discussion of the PaCES early palliative-care project and broader lung cancer advocacy.

ALK-positive Stage IV lung adenocarcinoma controlled with alectinib despite hemolytic anemia

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: ALK-positive

At 1 year after starting alectinib, the tumor had not regrown and treatment was continuing intermittently despite persistent mild anemia.

PubMed CentralRead more →